Literature DB >> 16482637

Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors.

Kazuyuki Yamazumi1, Toshiyuki Nakayama, Takafumi Kusaba, Chun Yang Wen, Ayumi Yoshizaki, Yuichi Yakata, Takeshi Nagayasu, Ichiro Sekine.   

Abstract

AIM: There is strong evidence that interleukin-11 (IL-11) is involved in the regulation of tumor progression, cellular growth and differentiation. Recently, interleukin-11 receptor (IL-11R) has been detected on some cancer cells. In this study, we investigated the expression of IL-11 and IL-11R in colorectal adenocarcinoma.
METHODS: To elucidate the involvement of IL-11 and IL-11Ra in human intestinal adenocarcinomas, we examined 115 cases of surgically resected human colonic adenocarcinoma and 11 cases of adenoma by immunohistochemistry and Western blotting.
RESULTS: Among 115 cases of adenocarcinoma, 100 cases (87.0%) showed positive staining in the cytoplasm of carcinoma cells for the IL-11, and 87 cases (75.6%) were positive for the IL-11Ra. Six cases (54.5%) and four cases (36.4%) of 11 adenomas were positive for IL-11 and IL-11Ra, respectively. The expression of IL-11Ra correlated with the histological differentiation (P = 0.033503), the depth of tumor invasion (P = 0.006395), Dukes'classification (P = 0.015648) and lymphatic invasion (P = 0.003865). However, the expression of IL-11Ra was not correlated with the venous invasion and the presence of lymph node metastasis. The expression of IL-11 was not correlated with any clinicopathological factors. In Western blot analysis, two human colorectal carcinoma cell lines and four tissues of surgically resected human carcinoma expressed both IL-11 and IL-11Ra proteins.
CONCLUSION: IL-11 and IL-11Ra are highly expressed in human colorectal adenocarcinoma and the IL-11Ra expression is correlated with clinicopathological factors. These findings suggest that the expression of IL-11Ra is an important factor for the invasion of human colorectal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16482637      PMCID: PMC4066046          DOI: 10.3748/wjg.v12.i2.317

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

2.  STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells.

Authors:  Cheng-Yong Yu; Lihua Wang; Alexander Khaletskiy; William L Farrar; Andrew Larner; Nancy H Colburn; Jian Jian Li
Journal:  Oncogene       Date:  2002-06-06       Impact factor: 9.867

3.  Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures.

Authors:  D C Keller; X X Du; E F Srour; R Hoffman; D A Williams
Journal:  Blood       Date:  1993-09-01       Impact factor: 22.113

4.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis.

Authors:  Tong-Xin Xie; Daoyan Wei; Mingguang Liu; Allen C Gao; Francis Ali-Osman; Raymond Sawaya; Suyun Huang
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

5.  Importance of tumor pathology and morphology in patients with surgically resected colon cancer. Findings from the Gastrointestinal Tumor Study Group.

Authors:  S M Steinberg; K W Barwick; D M Stablein
Journal:  Cancer       Date:  1986-09-15       Impact factor: 6.860

6.  Identification of FAP locus genes from chromosome 5q21.

Authors:  K W Kinzler; M C Nilbert; L K Su; B Vogelstein; T M Bryan; D B Levy; K J Smith; A C Preisinger; P Hedge; D McKechnie
Journal:  Science       Date:  1991-08-09       Impact factor: 47.728

7.  Identification of a chromosome 18q gene that is altered in colorectal cancers.

Authors:  E R Fearon; K R Cho; J M Nigro; S E Kern; J W Simons; J M Ruppert; S R Hamilton; A C Preisinger; G Thomas; K W Kinzler
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

Review 8.  Cutaneous leukemia inhibitory factor and its potential role in the development of skin tumors.

Authors:  Roddie C McKenzie; Jacek Szepietowski
Journal:  Dermatol Surg       Date:  2004-02       Impact factor: 3.398

9.  Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.

Authors:  Patricia Ault; Hagop Kantarjian; Mary Alma Welch; Francis Giles; Mary Beth Rios; Jorge Cortes
Journal:  Leuk Res       Date:  2004-06       Impact factor: 3.156

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  14 in total

1.  Expression of connective tissue growth factor and interleukin-11 in intratumoral tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Authors:  Zuo-Lin Xiang; Zhao-Chong Zeng; Jia Fan; Zhao-You Tang; Hai-Ying Zeng
Journal:  Mol Biol Rep       Date:  2011-12-29       Impact factor: 2.316

2.  Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma.

Authors:  Zuo-Lin Xiang; Zhao-Chong Zeng; Zhao-You Tang; Jia Fan; Jian He; Hai-Ying Zeng; Xiao-Dong Zhu
Journal:  Oncologist       Date:  2011-06-10

3.  A clinicopathological model to predict bone metastasis in hepatocellular carcinoma.

Authors:  Zuo-Lin Xiang; Zhao-Chong Zeng; Jia Fan; Wei-Zhong Wu; Jian He; Hai-Ying Zeng; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-14       Impact factor: 4.553

4.  Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells.

Authors:  Barbara Onnis; Nicole Fer; Annamaria Rapisarda; Victor S Perez; Giovanni Melillo
Journal:  J Clin Invest       Date:  2013-03-15       Impact factor: 14.808

5.  IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells.

Authors:  Hatem A Elshabrawy; Michael V Volin; Abdul B Essani; Zhenlong Chen; Iain B McInnes; Katrien Van Raemdonck; Karol Palasiewicz; Shiva Arami; Mark Gonzalez; Hossam M Ashour; Seung-Jae Kim; Guofei Zhou; David A Fox; Shiva Shahrara
Journal:  Angiogenesis       Date:  2018-01-11       Impact factor: 9.596

Review 6.  RCAN1-mediated calcineurin inhibition as a target for cancer therapy.

Authors:  Mengyi Lao; Xiaozhen Zhang; Hanshen Yang; Xueli Bai; Tingbo Liang
Journal:  Mol Med       Date:  2022-06-18       Impact factor: 6.376

7.  Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.

Authors:  Kurt J Sales; Vivien Grant; Ian H Cook; David Maldonado-Pérez; Richard A Anderson; Alistair R W Williams; Henry N Jabbour
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  Induction of cytokine gene expression in human thyroid epithelial cells irradiated with HZE particles (iron ions).

Authors:  Jenine K Sanzari; Manunya Nuth; Ann R Kennedy
Journal:  Radiat Res       Date:  2009-10       Impact factor: 2.841

9.  Interleukin 11 inhibits human trophoblast invasion indicating a likely role in the decidual restraint of trophoblast invasion during placentation.

Authors:  Premila Paiva; Lois A Salamonsen; Ursula Manuelpillai; Evdokia Dimitriadis
Journal:  Biol Reprod       Date:  2008-11-05       Impact factor: 4.285

10.  Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma.

Authors:  Joanne Yap; Lois A Salamonsen; Tom Jobling; Peter K Nicholls; Evdokia Dimitriadis
Journal:  Reprod Biol Endocrinol       Date:  2010-06-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.